Trans-sialidase recombinant protein mixed with CpG motif-containing oligodeoxynucleotide induces protective mucosal and systemic trypanosoma cruzi immunity involving CD8+ CTL and B cell-mediated cross-priming.
about
Evasion of the Immune Response by Trypanosoma cruzi during Acute InfectionThe Combined Deficiency of Immunoproteasome Subunits Affects Both the Magnitude and Quality of Pathogen- and Genetic Vaccination-Induced CD8+ T Cell Responses to the Human Protozoan Parasite Trypanosoma cruziRelevance of the diversity among members of the Trypanosoma cruzi trans-sialidase family analyzed with camelids single-domain antibodies.Intranasal vaccinations with the trans-sialidase antigen plus CpG Adjuvant induce mucosal immunity protective against conjunctival Trypanosoma cruzi challenges.Co-administration of a plasmid DNA encoding IL-15 improves long-term protection of a genetic vaccine against Trypanosoma cruziCD8(+) T cell-mediated immunity during Trypanosoma cruzi infection: a path for vaccine development?Protective efficacy of Toxoplasma gondii calcium-dependent protein kinase 1 (TgCDPK1) adjuvated with recombinant IL-15 and IL-21 against experimental toxoplasmosis in miceTc52 amino-terminal-domain DNA carried by attenuated Salmonella enterica serovar Typhimurium induces protection against a Trypanosoma cruzi lethal challenge.Poly(I:C)/alum mixed adjuvant priming enhances HBV subunit vaccine-induced immunity in mice when combined with recombinant adenoviral-based HBV vaccine boostingPresentation of soluble antigens to CD8+ T cells by CpG oligodeoxynucleotide-primed human naive B cells.Recombinant yellow fever viruses elicit CD8+ T cell responses and protective immunity against Trypanosoma cruziDeficiency of antigen-specific B cells results in decreased Trypanosoma cruzi systemic but not mucosal immunity due to CD8 T cell exhaustion.Oral exposure to Trypanosoma cruzi elicits a systemic CD8⁺ T cell response and protection against heterotopic challengeImmune responses to gp82 provide protection against mucosal Trypanosoma cruzi infectionECG detection of murine chagasic cardiomyopathy.Importance of the CCR5-CCL5 axis for mucosal Trypanosoma cruzi protection and B cell activation.B cells are critical to T-cell-mediated antitumor immunity induced by a combined immune-stimulatory/conditionally cytotoxic therapy for glioblastoma.B-Cell Response during Protozoan Parasite InfectionsCostimulatory Effects of an Immunodominant Parasite Antigen Paradoxically Prevent Induction of Optimal CD8 T Cell Protective Immunity.Th17 Cells Are More Protective Than Th1 Cells Against the Intracellular Parasite Trypanosoma cruziAn immunoinformatic approach for identification of Trypanosoma cruzi HLA-A2-restricted CD8(+) T cell epitopes.CpG and interleukin-15 synergize to enhance IFN-γ production by activated CD8+ T cellsNovel protective antigens expressed by Trypanosoma cruzi amastigotes provide immunity to mice highly susceptible to Chagas' disease.Cholera toxin and Escherichia coli heat-labile enterotoxin, but not their nontoxic counterparts, improve the antigen-presenting cell function of human B lymphocytesLong-Term Immunity to Trypanosoma cruzi in the Absence of Immunodominant trans-Sialidase-Specific CD8+ T Cells.CD8+ T cells specific for immunodominant trans-sialidase epitopes contribute to control of Trypanosoma cruzi infection but are not required for resistance.Chagas' disease: an update on immune mechanisms and therapeutic strategiesPerforin and gamma interferon expression are required for CD4+ and CD8+ T-cell-dependent protective immunity against a human parasite, Trypanosoma cruzi, elicited by heterologous plasmid DNA prime-recombinant adenovirus 5 boost vaccination.The endless race between Trypanosoma cruzi and host immunity: lessons for and beyond Chagas disease.Optimizing vaccine development.Advances and challenges towards a vaccine against Chagas disease.Gene-deleted live-attenuated Trypanosoma cruzi parasites as vaccines to protect against Chagas disease.Trans-sialidase from Trypanosoma brucei as a potential target for DNA vaccine development against African trypanosomiasis.An ImmunoSignature test distinguishes Trypanosoma cruzi, hepatitis B, hepatitis C and West Nile virus seropositivity among asymptomatic blood donors.Trans-sialidase-based vaccine candidate protects against Trypanosoma cruzi infection, not only inducing an effector immune response but also affecting cells with regulatory/suppressor phenotype.T-bet-dependent regulation of CD8+ T-cell expansion during experimental Trypanosoma cruzi infection.Differential immune response in mice immunized with the A, R or C domain from TcSP protein of Trypanosoma cruzi or with the coding DNAs.T-bet-independent effects of IL-12 family cytokines on regulation of Th17 responses to experimental T. cruzi infection.Comparative analysis of antigen-targeting sequences used in DNA vaccines.Down Modulation of Host Immune Response by Amino Acid Repeats Present in a Trypanosoma cruzi Ribosomal Antigen.
P2860
Q26772721-B4CB316A-040B-48ED-8015-5BCD8A3F0DC6Q27314524-A8460628-A2BA-47D0-8FF3-9D27C18BE225Q33379102-C707DA8D-B8F9-435C-9938-040A2BF69F6EQ33675887-A4490A61-54F8-4CA8-9B80-60BB28496C25Q33847435-A2E0299A-2FEA-49D7-9B23-3692CC7429A8Q33914939-3912B516-3CFA-4BCD-9513-A2A262A65CEDQ34196487-1227A6A1-0FC2-431E-BE2F-C71C6A615983Q34298752-0299FD4E-A257-437C-9236-33A857A9A89BQ34555824-7C6204F8-DB7D-4459-AE10-FFBA18E2DBA5Q34574238-A2EE881C-E6A2-4FE5-98A3-EF9CB8E8598EQ34635043-95EFD1B6-6F20-4F82-AEA3-C4D700731F5FQ35071882-BFF3DA19-6280-4ECC-94BE-86F8CE05334DQ35139381-93FCC7D2-3600-47EA-80F4-8AA046786938Q35148043-35502D78-AB39-47BD-B848-558FF3F8936AQ35148047-368EA9B7-2551-4456-B4F1-B66BA0D2CD06Q35149267-70C3BF4F-AD4B-480F-8E9D-ABEC519E4323Q35444346-78D49A64-0B59-4E60-837A-4D75C0FA618CQ35725257-1F61FE7F-CD08-4E5F-A0AB-11CC316C6671Q36136972-BA42B30B-F4B1-44AB-AD0F-D2E36988D92DQ36151179-A4F1B0BB-53BD-4E6D-B981-E85579E2D57AQ36256258-256D813E-BF73-4F7E-87F4-E44D39813469Q36665239-99B646DF-A783-4672-8510-D387C9A03AB6Q36844914-31CE9BB2-2853-447A-A639-86537430F283Q37191283-AFE316C8-AAD4-41AF-9AEC-0D5C8BFBC4B3Q37199864-81BE0877-7D57-4040-85CB-0C458A7840D9Q37200211-D9DDF4AA-F9DD-41A7-B025-A58619DC0D78Q37310959-563A40EC-519C-4B31-80DF-EA1DA046E702Q37355936-BB1E6D44-7FF3-4E50-A9D7-E5B3B0766ECCQ37788829-74877FD0-4B8F-4690-AFD7-AC41D83E8EC4Q37883493-19A88071-5A2D-44B8-AB86-9C32EFCAA8BDQ37952062-772ED43A-7B8C-42FB-8681-9FBE21F98B96Q38286350-3D97DF5A-2F2F-44EE-A498-61CCD2C54B49Q39463391-6020355B-64EC-4E39-A547-8C51DD13EAE8Q40057259-36D15F12-8575-4D32-9659-55E28824F521Q41709177-34F13AB0-B9BA-4D3C-8F48-E4A58065B743Q43640153-93FA0E57-34A2-4F04-8C68-FC7BB28961BDQ44270532-A97E9A44-5D94-40A9-B068-A66BF82CFD6AQ44959197-28232445-C575-46C7-9278-63DED1196673Q45986032-5344A185-E205-4388-B74C-D8F66A3B338BQ47161629-10E8EABF-E4F9-41E6-93ED-7ADA4150C225
P2860
Trans-sialidase recombinant protein mixed with CpG motif-containing oligodeoxynucleotide induces protective mucosal and systemic trypanosoma cruzi immunity involving CD8+ CTL and B cell-mediated cross-priming.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Trans-sialidase recombinant pr ...... B cell-mediated cross-priming.
@en
type
label
Trans-sialidase recombinant pr ...... B cell-mediated cross-priming.
@en
prefLabel
Trans-sialidase recombinant pr ...... B cell-mediated cross-priming.
@en
P2093
P1476
Trans-sialidase recombinant pr ...... B cell-mediated cross-priming
@en
P2093
Daniel F Hoft
José R C Vasconcelos
Maurício M Rodrigues
Olivia K Giddings
P304
P356
10.4049/JIMMUNOL.179.10.6889
P407
P50
P5008
P577
2007-11-01T00:00:00Z